Published • loading... • Updated
FDA Clears Takeda’s Mimrylo for Polycythemia Vera, Introducing a Novel Treatment Option
Summary by Patient Worthy
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
On August 28, the FDA approved rusfertide (Mimrylo) for the treatment of erythrocytosis in adults.
FDA Clears Takeda’s Mimrylo for Polycythemia Vera, Introducing a Novel Treatment Option
As reported on MedCity News, the U.S. Food and Drug Administration has approved Takeda Pharmaceutical’s Mimrylo (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a rare blood cancer characterized by excessive production of red blood cells. The approval marks the arrival of the first therapy in a new class designed to […]
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
